Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Enzymotec presents Clinical Trials Strategy for Its Infant Nutrition Ingredients - Nutraceuticals World

What are you searching for?

Sign in
Research

Enzymotec presents Clinical Trials Strategy for Its Infant Nutrition Ingredients

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Enzymotec Ltd., Kfar Baruch, Israel, has announced an approved strategy for clinical trials of its lipid-based ingredient line for infant nutrition. This plan is part of a business development strategy to develop and market directly or through its affiliated companies a line of products mimicking the vital lipids found in mother’s milk, such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA). Enzymotec intends to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals in the coming months.
One of the studies recently completed was a controlled clinical trial on InFat. InFat is a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants’ well-being.
For further information: www.enzymotec.com

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics